Clinical Evidence for FeNO Testing: What Healthcare Teams Need to Know

Respiratory teams need more than a test result to make a defensible clinical decision. They need to know what question a measurement is intended to answer, how research applies to that question and how to communicate the reasoning across a care team. The clinical evidence for FeNO testing helps distinguish what research supports from assumptions that go beyond the evidence. Making that distinction part of clinical discussion can support clearer, more consistent decision-making.

This article explains how FeNO research is framed, what guideline recommendations do and do not imply, and how clinicians can interpret a result within the broader respiratory assessment. It also covers practical factors that affect reliable use, including measurement procedures, documentation, staff roles and equipment planning. The aim is to help healthcare professionals assess the evidence and decide how FeNO measurement may fit their setting, while keeping professional judgement central. For Canadian teams, this means connecting published guidance with local clinical questions and day-to-day workflow.

What clinical evidence for FeNO testing examines

FeNO evidence examines how nitric oxide in exhaled breath relates to airway biology and whether measurement adds useful information in specific respiratory-care situations. When reviewing a study, look at three things: the population studied, the measurement method and the clinical question. Findings from one group or use case may not apply directly to another.

What does a FeNO measurement represent?

Fractional exhaled nitric oxide (FeNO) is the concentration of nitric oxide measured in a person’s exhaled breath under specified test conditions. The “fractional” value is commonly reported in parts per billion (ppb). Nitric oxide is produced in the airways, and FeNO is studied as a signal associated with Type 2 airway inflammation. It does not directly measure airflow, lung volumes or gas exchange, so it answers a different question from spirometry. The Exhaled nitric oxide (FeNO) in medicine overview describes the biological basis and measurement approaches. For clinicians reviewing research, distinguishing a biomarker from a physiological lung-function measure helps define what a study outcome can support.

Which clinical questions can FeNO help inform?

Research and guidelines examine whether FeNO adds information during asthma assessment and whether it can assist treatment decisions in selected settings. The Global Initiative for Asthma’s 2026 report includes FeNO as a complementary test in asthma diagnosis, with a strong recommendation for children and a conditional recommendation for adults. The American Thoracic Society’s 2021 guideline addresses using FeNO alongside usual care to guide asthma treatment. These recommendations are specific to their contexts. They do not mean every patient will benefit from testing.

When reviewing a study or protocol, identify whether it addresses diagnosis, inflammatory phenotype or treatment guidance. Then consider whether the participants resemble the patients being assessed. This keeps the evidence connected to the clinical question and helps prevent extending findings beyond the population or purpose studied.

What the clinical evidence supports, and where FeNO has limits

The clinical evidence for FeNO testing supports a defined role: adding information about Type 2 airway inflammation to selected asthma assessment and management decisions. Evidence about a test’s role is distinct from a guideline recommendation, which also reflects clinical judgement about how that test fits into care. Neither makes FeNO definitive for every patient or clinical question.

Where evidence may support clinical use

Higher FeNO can be associated with eosinophilic airway inflammation and a greater likelihood of corticosteroid responsiveness. This may make the measurement informative when clinicians assess suspected asthma or consider inflammatory features in a person with asthma. The 2026 Global Initiative for Asthma (GINA) report includes FeNO as a complementary diagnostic test, with different recommendation strength for children and adults. The American Thoracic Society’s 2021 guideline supports using FeNO alongside usual care to help guide asthma treatment. Both recommendations concern adjunctive use, not decisions based on FeNO alone.

Why FeNO evidence does not make the test definitive

Study findings and clinical recommendations do not establish that one result can confirm or exclude asthma, or determine treatment by itself. The Canadian Thoracic Society’s 2021 asthma guideline was cautious about routine FeNO measurement for assessing asthma control and identified diagnostic accuracy as an area requiring further evidence. Its scope differs from GINA’s and the ATS treatment guideline, so read each recommendation in context. CTS published a severe-asthma guideline in September 2026; apply current Canadian guidance to the relevant clinical population.

Interpretation also depends on the patient and the clinical question. ATS interpretation thresholds differ for adults and children: values considered low are below 25 ppb in adults and below 20 ppb in children; intermediate ranges are 25-50 ppb and 20-35 ppb, respectively; high values are above 50 ppb and 35 ppb. Intermediate results particularly require clinical context. Symptoms, history, treatment context and other investigations remain necessary. Treat thresholds as aids to interpretation, not standalone decision rules.

How clinicians can interpret FeNO evidence in practice

A consistent review process keeps a FeNO value tied to the clinical question it can inform. The clinical evidence for FeNO testing supports treating the result as one input, not as a replacement for clinical judgement or other investigations. A practical review can follow four steps:

1. Define the question. Clarify whether testing is intended to add information during asthma assessment or inform a management discussion. Consider the patient’s symptoms, history, age and current treatment before interpreting the number.
2. Review measurement quality. Confirm that the test was performed and recorded according to the device instructions and applicable technical guidance. The American Thoracic Society’s 2011 guideline on FeNO interpretation describes standardized measurement conditions, including controlled expiratory flow. If technique or result quality is uncertain, document the limitation rather than treating the value as definitive.
3. Interpret against appropriate guidance. Apply thresholds relevant to the patient group and clinical question, not a universal cut-off. ATS guidance distinguishes adult and paediatric ranges. Account for treatment and other factors that may influence the reading.
4. Integrate and document. Compare the result with symptoms, history, examination and investigations such as spirometry. Record how FeNO informs the assessment, what remains uncertain and whether other findings support the same interpretation.

What can affect interpretation?

ATS guidance identifies patient characteristics and clinical context as relevant to FeNO interpretation. Age and height, atopy or allergen exposure, smoking, and corticosteroid treatment can influence values; inhaled corticosteroids may lower FeNO. These factors do not invalidate a result, but they can affect what it means for an individual. Measurement technique matters as well, which is why standardized collection is central to comparison with published thresholds.

Use a consistent protocol and document relevant treatment and context so results can be interpreted responsibly over time. To explore FeNO measurement equipment for respiratory assessment, review Lothar Medical FeNO.

Bringing FeNO measurement into respiratory diagnostic workflows

FeNO measurement is easier to integrate when its clinical purpose, testing procedure and documentation fit the existing respiratory-care pathway. Before adding a measurement, map who will request and perform the test, how results will be reviewed and where findings will be recorded. Agreeing on these steps supports consistent interpretation without assuming the measurement will change care in every case.

Questions for integrating FeNO measurement

Start by identifying the intended users and patient groups, the point in the assessment when FeNO may be useful, and how staff will learn the testing protocol. Agree on how to record the result alongside relevant context, including the reason for testing, current treatment and other respiratory investigations. Decide how an incomplete or technically uncertain measurement will be documented and addressed.

When evaluating equipment, consider whether the proposed workflow supports the clinical question and the measurement procedures your team intends to follow. Review training needs, routine operation, result documentation and how the device will fit with existing assessment processes. Keep evaluation criteria tied to evidence and local workflow requirements. Do not assume device capabilities or clinical outcomes that have not been established. The respiratory therapy equipment procurement guide can help frame broader purchasing considerations for Canadian healthcare teams.

A Canadian resource for FeNO equipment

Novus Medical distributes Lothar Medical FeNO products in Canada. For teams assessing how FeNO measurement may fit within respiratory diagnostics, equipment selection is one part of planning; it is distinct from evidence of clinical benefit. A clear protocol, trained users and consistent documentation help connect the measurement to its intended role in assessment.

For Canadian healthcare teams exploring FeNO measurement equipment, view Lothar Medical FeNO as part of planning a respiratory diagnostic workflow.

Make FeNO part of a considered diagnostic pathway

Adding a biomarker to respiratory assessment is most useful when the team has a clear plan for reviewing and documenting the information. The clinical evidence for FeNO testing can guide that planning, but local protocols should reflect the patient population, intended clinical questions and applicable guidance. Align clinicians on when a measurement may add value, how it will be interpreted alongside other findings and how uncertainty will be recorded.

As your team evaluates respiratory diagnostic resources, consider how FeNO measurement fits with existing workflows and staff training. Novus Medical serves healthcare providers across Canada and offers Lothar Medical FeNO products. Explore Lothar Medical FeNO products from Novus Medical as you plan an evidence-informed approach to respiratory assessment.

Frequently Asked Questions

Can FeNO testing diagnose asthma on its own?

No. A FeNO result cannot replace the objective assessment used to establish asthma, including evaluation for variable expiratory airflow limitation. If a patient has asthma-like symptoms but the initial assessment is inconclusive, follow the applicable diagnostic pathway rather than treating FeNO as the deciding test. The result may contribute information, but diagnosis depends on the full clinical work-up.

Is FeNO testing useful when assessing asthma treatment?

It can be useful as one source of information, but a FeNO reading should not prompt a treatment change automatically. If symptoms persist, review factors such as medication use, inhaler technique and the patient’s recent clinical course before considering next steps. A result that differs from the expected picture can help identify questions for follow-up, but it does not provide a treatment instruction by itself.

What can affect a FeNO test result?

Patient characteristics, treatment and test technique can all affect how confidently a result can be interpreted. Follow the measurement device’s instructions and the clinic’s testing protocol, and record any departure from them. If a reading seems unexpected, consider whether the manoeuvre was completed as intended before drawing conclusions or comparing it with a previous measurement.

How should clinicians interpret a FeNO result?

Use the interpretive framework that matches the patient’s age and the clinical purpose of testing. A value near a decision boundary deserves particular care; avoid treating a small difference as a definite change in clinical status. Record the reasoning behind the interpretation, especially when the result does not align with the patient’s presentation or other assessment findings.

Can FeNO results be compared over time?

Yes, comparison can be informative when the testing approach is consistent. For serial measurements, use the same device and protocol where possible, and note the date and relevant treatment timing. If these conditions differ between visits, describe the difference in the record. A change in readings may reflect measurement context as well as a change in the patient’s status.